180 related articles for article (PubMed ID: 27386791)
1. New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach.
Pallagi E; Karimi K; Ambrus R; Szabó-Révész P; Csóka I
Int J Pharm; 2016 Sep; 511(1):151-160. PubMed ID: 27386791
[TBL] [Abstract][Full Text] [Related]
2. The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers.
Buttini F; Rozou S; Rossi A; Zoumpliou V; Rekkas DM
Eur J Pharm Sci; 2018 Feb; 113():64-76. PubMed ID: 29104067
[TBL] [Abstract][Full Text] [Related]
3. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
[TBL] [Abstract][Full Text] [Related]
4. [Formulation of new generation drug delivery system for dry powder inhalation.].
Chvatal A; Szabo B; Szabo-Revesz P; Ambrus R
Acta Pharm Hung; 2016; 86(3):75-83. PubMed ID: 29489079
[TBL] [Abstract][Full Text] [Related]
5. Adaptation of the quality by design concept in early pharmaceutical development of an intranasal nanosized formulation.
Pallagi E; Ambrus R; Szabó-Révész P; Csóka I
Int J Pharm; 2015 Aug; 491(1-2):384-92. PubMed ID: 26134895
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization and pulmonary pharmacokinetics of a new inhalable zanamivir dry powder.
Cai X; Yang Y; Xie X; Yu F; Yang Y; Yang Z; Zhang T; Mei X
Drug Deliv; 2016 Jul; 23(6):1962-71. PubMed ID: 26066037
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutical quality by design: product and process development, understanding, and control.
Yu LX
Pharm Res; 2008 Apr; 25(4):781-91. PubMed ID: 18185986
[TBL] [Abstract][Full Text] [Related]
8. Formulation Design of Dry Powders for Inhalation.
Weers JG; Miller DP
J Pharm Sci; 2015 Oct; 104(10):3259-88. PubMed ID: 26296055
[TBL] [Abstract][Full Text] [Related]
9. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
10. Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance.
Ezzati Nazhad Dolatabadi J; Hamishehkar H; Valizadeh H
Drug Dev Ind Pharm; 2015; 41(9):1431-7. PubMed ID: 25220930
[TBL] [Abstract][Full Text] [Related]
11. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
12. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
13. Preparation and Quality Evaluation of Salvianolic Acids and Tanshinones Dry Powder Inhalation.
Wang J; Zhai W; Yu J; Wang J; Dai J
J Pharm Sci; 2018 Sep; 107(9):2451-2456. PubMed ID: 29883664
[TBL] [Abstract][Full Text] [Related]
14. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
15. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA.
Jensen DK; Jensen LB; Koocheki S; Bengtson L; Cun D; Nielsen HM; Foged C
J Control Release; 2012 Jan; 157(1):141-8. PubMed ID: 21864597
[TBL] [Abstract][Full Text] [Related]
16. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
17. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules.
Sou T; Kaminskas LM; Nguyen TH; Carlberg R; McIntosh MP; Morton DA
Eur J Pharm Biopharm; 2013 Feb; 83(2):234-43. PubMed ID: 23183447
[TBL] [Abstract][Full Text] [Related]
18. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
Young PM; Salama RO; Zhu B; Phillips G; Crapper J; Chan HK; Traini D
Drug Dev Ind Pharm; 2015 May; 41(5):859-65. PubMed ID: 24811055
[TBL] [Abstract][Full Text] [Related]
19. Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
Miller DP; Tan T; Tarara TE; Nakamura J; Malcolmson RJ; Weers JG
Mol Pharm; 2015 Aug; 12(8):2582-93. PubMed ID: 26052676
[TBL] [Abstract][Full Text] [Related]
20. Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.
Bartos C; Pallagi E; Szabó-Révész P; Ambrus R; Katona G; Kiss T; Rahimi M; Csóka I
Eur J Pharm Sci; 2018 Oct; 123():475-483. PubMed ID: 30076956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
